Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 487 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALS Clear all
Recruiting Not applicable Interventional

Evaluation of a Structurally Suitable Neck Exoskeleton in Patients With Amyotrophic Lateral Sclerosis

NCT07491562
View directory record Official record
Conditions
ALS - Amyotrophic Lateral Sclerosis
Interventions
powered neck exoskeleton
Device
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 21, 2026, 10:31 AM EDT
Recruiting Not applicable Interventional

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

NCT07521930
View directory record Official record
Conditions
Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Muscular Disorders, Atrophic, Brain Stem Stroke, Spinal Cord Injuries (SCI), Muscular Dystrophies, Muscular Atrophy, Progressive, Pontine Hemorrhage, Pontine Infarction
Interventions
INTENT Neural Interface System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET

NCT03876002
View directory record Official record
Conditions
Healthy Volunteers, Amyotrophic Lateral Sclerosis
Interventions
[18F]PBR06
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 21, 2026, 10:31 AM EDT
Completed Not applicable Interventional

Determining Feasibility and Acceptability of Sharing Video Recordings With Patients With ALS and Caregivers

NCT04719403
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
HealthPAL
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 21, 2026, 10:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida

NCT01699451
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 21, 2026, 10:31 AM EDT
Available No phase listed Expanded access

Intermediate-size Patient Population Expanded Access Protocol

NCT07088159
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Tazbentetol
Drug
Lead sponsor
Spinogenix
Industry
Eligibility
18 Years to 85 Years
U.S. locations
16
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 10:31 AM EDT
Not listed Phase 1 Interventional

Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

NCT01348451
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
surgical implantation
Device
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 21, 2026, 10:31 AM EDT
Active, not recruiting Phase 2 Interventional

T-regulatory Cells in ALS

NCT04055623
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 21, 2026, 10:31 AM EDT
Completed Not applicable Interventional

Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS

NCT02469675
View directory record Official record
Conditions
Spinal Cord Injury (SCI), Amyotrophic Lateral Sclerosis (ALS)
Interventions
Transcranial magnetic stimulation, Median nerve stimulation, Cervical transcutaneous stimulation
Device
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
21 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 21, 2026, 10:31 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

NCT04948645
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis
Interventions
Fosigotifator, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 21, 2026, 10:31 AM EDT
Recruiting Phase 1 Interventional

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

NCT07204977
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Acamprosate calcium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 10:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps

NCT04998305
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Muscle Cramp
Interventions
TJ-68, Placebo
Drug
Lead sponsor
Hiroshi Mitsumoto
Other
Eligibility
20 Years to 84 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 21, 2026, 10:31 AM EDT
Recruiting Phase 2 Interventional

A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)

NCT07071935
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure, Neuromuscular Disease Patients, Neuromuscular Disease, Respiratory Insufficiency, Respiratory Insufficiency Requiring Mechanical Ventilation, Positive Pressure Ventilation, Non-invasive Ventilation, Non-invasive Ventilation Support, Non-invasive Ventilatory Support
Interventions
Non-invasive ventilation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania • Philadelphi, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 10:31 AM EDT
Completed Phase 3 Interventional Results available

A Study for Patients Who Completed VITALITY-ALS (CY 4031)

NCT02936635
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
tirasemtiv
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 21, 2026, 10:31 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Evaluation of BIIB067 (Tofersen)

NCT03070119
View directory record Official record
Conditions
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Interventions
Tofersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 21, 2026, 10:31 AM EDT
Completed Phase 1Phase 2 Interventional

Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS

NCT07095712
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
nL-TARD-001
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
49 Years to 49 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 10:31 AM EDT
Terminated No phase listed Observational Results available

Lower Extremity Fixation In Neuropathic Patients Study

NCT04607044
View directory record Official record
Conditions
Neuropathy, Charcot; Disease (Etiology)
Interventions
SALVATION™ EXTERNAL FIXATION
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Trinity, Florida • West Chester, Pennsylvania • Sparta, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 21, 2026, 10:31 AM EDT
Completed Not applicable Interventional Results available

Remotely Supervised tDCS for Slowing ALS Disease Progression

NCT04866771
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Transcranial Direct Current Stimulation (tDCS), Sham tDCS + anodal tDCS
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 21, 2026, 10:31 AM EDT
Recruiting Not applicable Interventional

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)

NCT06511934
View directory record Official record
Conditions
Brainstem Stroke, ALS, Tetraplegia, Spinal Cord Injuries, Cervical Spinal Cord Injury
Interventions
BrainGate Neural Interface System
Device
Lead sponsor
Leigh R. Hochberg, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 10:31 AM EDT
Not yet recruiting Phase 1 Interventional

A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).

NCT07883590
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Interventions
LY3873862, CYP450 Drug Cocktail, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 10:31 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders

NCT05116943
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2030
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 10:31 AM EDT
Temporarily Not Available No phase listed Expanded access

Intermediate Expanded Access Protocol CNMAu8.EAP04

NCT06408727
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, PALS
Interventions
CNM-Au8
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years and older
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Chicago, Illinois • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 10:31 AM EDT
Completed Phase 2 Interventional

Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease

NCT00324454
View directory record Official record
Conditions
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Interventions
Levetiracetam
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 21, 2026, 10:31 AM EDT
Approved For Marketing No phase listed Expanded access

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

NCT05286372
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 21, 2026, 10:31 AM EDT